HSP70 as a Diagnostic and Prognostic Marker in Egyptian Women With Breast Cancer

We examined heat shock protein 70 (HSP70) in 155 cases in Egyptian patients with breast cancer. HSP70 was expressed in both serum (98.3%) and tumor tissue (90%) of cancer cases. A strong positive correlation was found between HSP70 immunohistochemistry and enzyme-linked immunosorbent assay. HSP70 can serve as a breast cancer biomarker for early screening, diagnosis, and follow-up. Background: Heat shock protein 70 (HSP70) is a significant cellular stress response protein that has intrinsic and extrinsic pathways to protect cells against apoptosis. It is one of the most induced proteins in cancer cells. The aim of the present study is to investigate the significant role of the HSP70 expression in Egyptian patients with breast cancer (BC) and its potential to be as a diagnostic and prognostic marker. Materials and Methods: HSP70 was examined in 155 cases in this prospective study; patients were subdivided into 3 groups: 60 patients with malignant metastatic disease, 60 patients with malignant non-metastatic disease, and 35 patients with benign lesions as control. HSP70 expression was detected using enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC). Results: Most cases of breast cancer expressed HSP70 in both serum (98.3%) and tumor tissue (90%). A strong positive correlation was found between HSP70 IHC and ELISA (r = 0.811). The mean HSP70 levels, as detected in both patients' serum by ELISA and tumor tissue by IHC, was significantly higher in patients with BC than in benign cases (P=.001). HSP70 was significantly higher in patients with metastatic BC than in those with non-metastatic BC (P= .001). HSP70 showed positive correlation with tumor size (pT stage) and number of lymph node metastases (P <=.001). Conclusion: HSP70 is over-expressed in patients with metastatic and non-metastatic BC than in benign cases. A high level of HSP70 either in patient's serum or in tumor tissue correlated significantly with advanced disease in patients with BC. This present study suggests that HSP70 can serve as a BC biomarker for early screening, diagnosis, and follow-up. (C) 2020 Elsevier Inc. All rights reserved.